- Home
- VNT vs KRYS Comparison
VNT vs KRYS Comparison
Compare VNT & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNT
- KRYS
- Stock Information
- Founded
- VNT 2019
- KRYS 2015
- Country
- VNT United States
- KRYS United States
- Employees
- VNT N/A
- KRYS N/A
- Industry
- VNT Industrial Machinery/Components
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VNT Industrials
- KRYS Health Care
- Exchange
- VNT Nasdaq
- KRYS Nasdaq
- Market Cap
- VNT 4.4B
- KRYS 3.6B
- IPO Year
- VNT N/A
- KRYS 2017
- Fundamental
- Price
- VNT $35.74
- KRYS $125.96
- Analyst Decision
- VNT Buy
- KRYS Strong Buy
- Analyst Count
- VNT 7
- KRYS 8
- Target Price
- VNT $44.20
- KRYS $211.13
- AVG Volume (30 Days)
- VNT 992.8K
- KRYS 436.2K
- Earning Date
- VNT 05-01-2025
- KRYS 05-06-2025
- Dividend Yield
- VNT 0.28%
- KRYS N/A
- EPS Growth
- VNT N/A
- KRYS 109.01
- EPS
- VNT 2.46
- KRYS 4.16
- Revenue
- VNT $2,964,300,000.00
- KRYS $333,448,000.00
- Revenue This Year
- VNT $2.28
- KRYS $48.66
- Revenue Next Year
- VNT $5.05
- KRYS $49.81
- P/E Ratio
- VNT $14.54
- KRYS $30.31
- Revenue Growth
- VNT N/A
- KRYS 247.53
- 52 Week Low
- VNT $27.22
- KRYS $122.80
- 52 Week High
- VNT $41.61
- KRYS $219.34
- Technical
- Relative Strength Index (RSI)
- VNT 57.27
- KRYS 31.65
- Support Level
- VNT $35.07
- KRYS $123.03
- Resistance Level
- VNT $36.14
- KRYS $127.59
- Average True Range (ATR)
- VNT 0.59
- KRYS 4.59
- MACD
- VNT -0.15
- KRYS 0.39
- Stochastic Oscillator
- VNT 29.42
- KRYS 18.15
About VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.